Immunic, Inc. (IMUX)

1.1100 +0.0900 (+8.82%) At close: 04:00PM EDT

Immunic, Inc.

1200 Avenue of the Americas
Suite 200
New York, NY 10036
United States
332 255 9818
https://imux.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 80

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Duane D. Nash J.D., M.B.A., M.D.	Executive Chairman	504.57k	N/A	1971
Dr. Daniel Vitt Ph.D.	CEO, President & Director	869.96k	N/A	1968
Mr. Glenn Whaley CPA	Chief Financial Officer	576.85k	N/A	1968
Dr. Andreas Muehler M.D., Ph.D.	Chief Medical Officer	694.86k	N/A	1965
Dr. Hella Kohlhof	Chief Scientific Officer	N/A	N/A	1974
Jessica Breu	Head of Investor Relations & Communications	N/A	N/A	N/A
Mr. Inderpal Singh	General Counsel	N/A	N/A	1967
Mr. Patrick Walsh	Chief Business Officer	N/A	N/A	1984

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Corporate governance

Immunic, Inc.’s ISS governance QualityScore as of 1 June 2024 is 7. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.